LEIDEN, Netherlands & CAMBRIDGE, Mass. - ProQR (NASDAQ:PRQR) Therapeutics N.V. (NASDAQ:PRQR), a biopharmaceutical company focused on RNA therapies, announced today that it has successfully defended a key patent in Japan related to its proprietary Axiomer RNA editing platform. The patent, which involves the use of modified oligonucleotides for targeted RNA editing, was upheld against an opposition filed in September 2023.
The Japanese Patent Office dismissed the challenge, confirming the novelty and inventiveness of the claims, thus maintaining the patent's validity. This decision reinforces ProQR's intellectual property (IP) position in the RNA editing field, where the company has established a significant patent estate.
René Beukema, ProQR's Chief Corporate Development Officer and General Counsel, expressed confidence in the company's IP strength, stating that the outcome in Japan aligns with previous successes in defending their patents across various jurisdictions. The company views the protection of its IP as critical to its long-term strategy and intends to continue defending its technologies.
ProQR's Axiomer platform, which was first patented in 2014, enables precise RNA editing using the body's own ADAR enzymes. This technology has the potential to correct RNA mutations or modulate protein expression to treat diseases. ProQR's patent portfolio includes over 13 published patent families and 27 patents, with additional unpublished applications, highlighting its commitment to expanding its IP around ADAR-mediated RNA editing.
This press release also includes forward-looking statements regarding the potential of ProQR's Axiomer technology and its product candidates. However, the company acknowledges that its actual results may vary due to various risks and uncertainties.
The information for this article is based on a press release statement from ProQR Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.